Rep. Gilbert Ray Cisneros, Jr. Buys Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares

10 Apr 2026, 17:08 by Doug Wharley · The Cerbat Gem

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Halozyme Therapeutics stock on March 9th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $0.74 on Friday, hitting $67.82. 1,000,039 shares of the stock were exchanged, compared to its average volume of 1,833,853. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. The firm has a market capitalization of $8.03 billion, a PE ratio of 27.24, a P/E/G ratio of 0.27 and a beta of 1.03. Halozyme Therapeutics, Inc. has a one year low of $47.50 and a one year high of $82.22. The firm’s 50 day moving average is $69.40 and its two-hundred day moving average is $69.05.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The company had revenue of $451.77 million during the quarter, compared to the consensus estimate of $446.13 million. During the same quarter in the prior year, the business earned $1.26 EPS. The firm’s revenue for the quarter was up 51.6% compared to the same quarter last year. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total transaction of $1,284,800.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $49,322,187.20. This trade represents a 2.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 20,000 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $67.80, for a total value of $1,356,000.00. Following the transaction, the chief operating officer directly owned 14,366 shares in the company, valued at approximately $974,014.80. This represents a 58.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 118,857 shares of company stock worth $8,279,587. 2.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have commented on the company. Wall Street Zen downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 21st. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Weiss Ratings downgraded Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Tuesday, February 24th. Wells Fargo & Company raised their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. Finally, HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Six analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Hold” and a consensus price target of $78.56.

Read Our Latest Analysis on HALO

Institutional Trading of Halozyme Therapeutics

A number of large investors have recently modified their holdings of HALO. DLD Asset Management LP raised its holdings in shares of Halozyme Therapeutics by 20.0% during the 3rd quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock valued at $2,200,200,000 after buying an additional 5,000,000 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Halozyme Therapeutics by 29.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after buying an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Halozyme Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after buying an additional 25,731 shares in the last quarter. Norges Bank purchased a new position in shares of Halozyme Therapeutics during the 4th quarter valued at about $128,201,000. Finally, William Blair Investment Management LLC purchased a new position in shares of Halozyme Therapeutics during the 4th quarter valued at about $124,031,000. Institutional investors own 97.79% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.